Trigenesis Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 09-12-2024
- Paid Up Capital ₹ 3.60 Cr
as on 09-12-2024
- Company Age 20 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 4.85 Cr
as on 09-12-2024
- Revenue 0.71%
(FY 2022)
- Profit 12.64%
(FY 2022)
- Ebitda 66.59%
(FY 2022)
- Net Worth -38.88%
(FY 2022)
- Total Assets -14.82%
(FY 2022)
About Trigenesis Lifesciences
The Corporate was formerly known as Trigenesis Lifescience Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 3.60 Cr.
The company has closed loans amounting to ₹4.85 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Vijay Nahar and Bhawarlal serve as directors at the Company.
- CIN/LLPIN
U24231KA2004PTC034182
- Company No.
034182
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Jun 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Trigenesis Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijay Nahar  | Director | 15-Jul-2019 | Current |
| Bhawarlal | Director | 16-Dec-2019 | Current |
Financial Performance and Corporate Structure Insights of Trigenesis Lifesciences.
Trigenesis Lifesciences Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 0.71% increase. The company also saw a substantial improvement in profitability, with a 12.64% increase in profit. The company's net worth observed a substantial decline by a decrease of 38.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Trigenesis Lifesciences?
In 2022, Trigenesis Lifesciences had a promoter holding of 100.00%. The company had 2 Subsidiaries and 2 Associate Companies. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Trigenesis Biosciences Private LimitedActive 13 years 11 monthsVijay Nahar and Bhawarlal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 18 Jun 2021 | ₹1.00 Cr | Satisfied |
Hdfc Bank Limited Creation Date: 30 Nov 2012 | ₹2.25 Cr | Satisfied |
Bank Of India Creation Date: 25 Apr 2006 | ₹1.00 Cr | Satisfied |
How Many Employees Work at Trigenesis Lifesciences?
Trigenesis Lifesciences has a workforce of 3 employees as of Mar 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Trigenesis Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Trigenesis Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
